Sagimet Biosciences (SGMT) Stock Price, News & Analysis

Company Overview

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes. The company’s research platform leverages a proprietary chemokine-targeted approach to address underlying disease mechanisms rather than solely treating symptoms. By focusing on the molecular cues that recruit pro-fibrotic cells, Sagimet aims to develop therapies with the potential for disease modification in conditions that today have limited treatment options.

Headquartered in the San Francisco Bay Area, Sagimet Biosciences operates research and development facilities that support both in-house discovery and collaborative initiatives with academic and industry partners. Since its formation in 2020, the company has built a team of scientists and clinicians with expertise in fibrosis biology, protein engineering and translational medicine. This multidisciplinary organization is structured to accelerate candidates from early discovery through proof-of-concept studies.

Sagimet’s leadership team is led by President and Chief Executive Officer Dr. Steven Landis, a recognized expert in fibrotic disease research and a co-founder of the company’s predecessor, Cirius Therapeutics. Under Dr. Landis’s guidance, Sagimet has established a clear clinical development plan for CM-101 and is advancing strategic collaborations to expand its pipeline. The company’s strategic vision is centered on delivering first-in-class and best-in-class therapies for patients with high-unmet-need fibrotic disorders.

Key Stats

• Today's Range: $6.86 to $7.25
• 50-Day Range: $6.91 to $10.24
• 52-Week Range: $1.73 to $11.41
• Volume: 347,394 shs
• Average Volume: 584,805 shs
• Market Capitalization: $228.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.67
• Consensus Rating: Buy

Sagimet Biosciences Stock Analysis - MarketRank™

Sagimet Biosciences scored higher than 67% of companies evaluated by MarketBeat, and ranked 333rd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Sagimet Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Sagimet Biosciences has a consensus price target of $25.67, representing about 265.1% upside from its current price of $7.03.

Amount of Analyst Coverage

Sagimet Biosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Sagimet Biosciences are expected to decrease in the coming year, from ($1.60) to ($4.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sagimet Biosciences is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sagimet Biosciences is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sagimet Biosciences has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.73% of the float of Sagimet Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Sagimet Biosciences has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sagimet Biosciences has recently decreased by 12.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sagimet Biosciences does not currently pay a dividend.

Dividend Growth

Sagimet Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.73% of the float of Sagimet Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Sagimet Biosciences has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sagimet Biosciences has recently decreased by 12.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.42

News Sentiment

Sagimet Biosciences has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Sagimet Biosciences this week, compared to 2 articles on an average week.

Search Interest

Only 10 people have searched for SGMT on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.

MarketBeat Follows

1 people have added Sagimet Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sagimet Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $771,805.00 in company stock.

Percentage Held by Insiders

14.70% of the stock of Sagimet Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

87.86% of the stock of Sagimet Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SGMT Stock Analysis - Frequently Asked Questions

How have SGMT shares performed this year?

Sagimet Biosciences' stock was trading at $4.50 at the start of the year. Since then, SGMT shares have increased by 56.2% and is now trading at $7.03.

How were Sagimet Biosciences' earnings last quarter?

Sagimet Biosciences Inc. (NASDAQ:SGMT) announced its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.20.

When did Sagimet Biosciences IPO?

Sagimet Biosciences (SGMT) raised $85 million in an IPO on Friday, July 14th 2023. The company issued 5,312,500 shares at a price of $16.00 per share.

Who are Sagimet Biosciences' major shareholders?

Top institutional shareholders of Sagimet Biosciences include Bridgeway Capital Management LLC (1.35%), Geode Capital Management LLC (0.87%), Raymond James Financial Inc. (0.86%) and Jump Financial LLC (0.48%). Insiders that own company stock include Enterprise Associates 13 L New, David Happel, Elizabeth Rozek, George Kemble, Eduardo Bruno Martins and Beth C Seidenberg.
View institutional ownership trends.

How do I buy shares of Sagimet Biosciences?

Shares of SGMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sagimet Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sagimet Biosciences investors own include XPeng (XPEV), Iovance Biotherapeutics (IOVA), Taiwan Semiconductor Manufacturing (TSM), Avino Silver & Gold Mines (ASM), Tenet Healthcare (THC) and Urogen Pharma (URGN).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/09/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SGMT
• CIK: 1400118
• Web: sagimet.com
• Phone: 650-561-8600
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sagimet Biosciences: $25.67
• High Price Target: $30.00
• Low Price Target: $12.00
• Potential Upside/Downside: +265.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -39.88%
• Return on Assets: -38.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.55
• Quick Ratio: 17.55

Sales & Book Value

• Annual Sales: $2 million
• Price / Sales: 114.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.08 per share
• Price / Book: 1.38

Miscellaneous

• Outstanding Shares: 32,520,000
• Free Float: 27,741,000
• Market Cap: $228.62 million
• Optionable: Optionable
• Beta: 3.35